Orforgliprondrug info
orforglipron 5.5 MG Oral Tablet [Foundayo]
What it is used for
FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective July 29, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
FOUNDAYO contains orforglipron, a GLP-1 receptor agonist. The molecular formula for orforglipron calcium is C 48 H 47 F 2 N 10 O 5.[0.5]Ca and the molecular weight is 902.0 g/mol. The chemical name is calcium bis{3-[(1 S,2 S )-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1 H -indazol-5-yl)-2-oxo-2,3-dihydro-1 H -imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5 H -pyrazolo[4,3- c ]pyridine-5-yl}carbonyl)-5-[(4 S )-2,2-dimethyloxan-4-yl]-1 H -indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5 H )-ide}. Orforglipron calcium has the following chemical structure: Orforglipron calcium is a white to practically white to light brown solid that is hygroscopic. Orforglipron calcium is insoluble in water. FOUNDAYO tablets contain 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg of orforglipron (equivalent to 0.817 mg, 2.554 mg, 5.619 mg, 9.194 mg, 14.81 mg, and 17.57 mg of orforglipron calcium, respectively) as film-coated, debossed tablets for oral use. Each tablet contains the following inactive ingredients: copovidone, crospovidone, magnesium stearate, microcrystalline cellulose, and sodium carbonate anhydrous. The tablet film-coating material contains polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. Additionally, the film coating of the: 0.8 mg and 9 mg tablets contain ferric oxide red and ferric oxide yellow 2.5 mg and 14.5 mg tablets contain ferric oxide yellow 5.5 mg and 17.2 mg tablets contain ferrosoferric oxide and ferric oxide red. Each tablet contains 10 mg or less of sodium. Chemical Structure
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective July 29, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance